Galectin Therapeutics Inc
$ 2.45
8.41%
17 Apr - close price
- Market Cap 148,770,000 USD
- Current Price $ 2.45
- High / Low $ 2.49 / 2.29
- Stock P/E N/A
- Book Value -1.97
- EPS -0.48
- Next Earning Report 2026-05-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.68 %
- ROE -37.28 %
- 52 Week High 7.13
- 52 Week Low 1.21
About
Galectin Therapeutics Inc., a clinical-stage biopharmaceutical company, is dedicated to the research and development of therapies for fibrotic, cancerous and other diseases. The company is headquartered in Norcross, Georgia.
Analyst Target Price
$11.00
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-26 | 2025-11-14 | 2025-08-14 | 2025-05-13 | 2025-03-27 | 2024-11-11 | 2024-08-13 | 2024-05-15 | 2024-03-29 | 2023-11-13 | 2023-08-14 | 2023-05-15 |
| Reported EPS | -0.08 | -0.13 | -0.12 | -0.1917 | -0.19 | -0.18 | -0.2 | -0.19 | -0.16 | -0.24 | -0.15 | -0.19 |
| Estimated EPS | -0.1 | -0.18 | -0.19 | -0.11 | -0.16 | -0.2 | -0.16 | -0.16 | -0.16 | -0.16 | -0.21 | -0.21 |
| Surprise | 0.02 | 0.05 | 0.07 | -0.0817 | -0.03 | 0.02 | -0.04 | -0.03 | 0 | -0.08 | 0.06 | 0.02 |
| Surprise Percentage | 20% | 27.7778% | 36.8421% | -74.2727% | -18.75% | 10% | -25% | -18.75% | 0% | -50% | 28.5714% | 9.5238% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: GALT
2026-04-16 13:10:31
Galectin Therapeutics announced it would present new data on its lead compound, GR-MD-02, at the AASLD Annual Meeting on November 12, 2012. The data will focus on GR-MD-02's ability to prevent and reverse fibrosis in animal models of non-alcoholic steatohepatitis (NASH). This presentation will further explain the mechanism by which GR-MD-02 improves NASH pathology.
2026-04-13 10:09:59
GALECTIN THERAPEUTICS INC (GALT) announced an SEC filing with Form EFFECT, indicating the effectiveness of its S-3 registration statement as of April 10, 2026, at 4:00 P.M. The filing and its sentiment are rated as neutral. The article provides an overview of GALT's recent news, SEC filings, and stock data.
2026-04-04 12:10:30
This article provides an overview of analyst insights, price targets, and recommendations for Galectin Therapeutics Inc. (PHPN.F). It highlights recent upgrades and downgrades by HC Wainwright & Co., including reiterations of "Buy" ratings and a downgrade to "Neutral." The stock closed at 2.1400 EUR with a slight decrease.
2026-04-04 02:09:27
Galectin Therapeutics Inc. (NASDAQ: GALT) has filed its annual report, detailing progress and setbacks in developing Belapectin, a Galectin-3 inhibitor, for MASH cirrhosis and cancer. The Phase 2b/3 NAVIGATE trial showed promise in subgroups but missed its primary endpoint in the overall intent-to-treat population, raising uncertainty for future Phase 3 plans. The company faces significant financial risks, with an accumulated deficit of $431 million and a cash runway projected only until April 2027, highlighting its reliance on a single financier and the need for additional capital.
2026-04-03 11:11:33
Galectin Therapeutics (GALT) has received an upgrade to a Zacks Rank #2 (Buy) due to positive shifts in its earnings outlook and improved earnings forecasts. This upgrade, distinct from subjective Wall Street analyst ratings, is based on measurable changes in earnings per share estimates, which often influence short-term stock prices. The company's earnings for fiscal year 2026 are projected at -$0.31 per share, with forecasts steadily increasing, and the Zacks Consensus Estimate rising by 24.4% over the past quarter, suggesting potential for significant investor interest and stock appreciation.
2026-04-03 11:10:03
HC Wainwright has increased its FY2026 earnings estimates for Galectin Therapeutics Inc. (NASDAQ:GALT) to ($0.31) per share, up from ($0.41) per share, while maintaining a 'Buy' rating and an $11.00 price target. This revised outlook indicates improved financial prospects for the biotech company, which focuses on developing therapies for fibrotic, inflammatory, and malignant diseases. The firm also provided FY2027 earnings estimates of ($0.33) per share.
